Comphya SA

About Comphya SA

Comphya SA is a Swiss medical device company focused on developing innovative therapies for erectile dysfunction, particularly for patients who do not respond to oral treatments. Their mission is to provide a better, more comfortable solution through neurostimulation technology.

Products & Services

CaverSTIM:A novel implantable neurostimulator device designed to restore natural penile erection through neuromodulation. It targets patients with erectile dysfunction caused by mechanical nerve damage, such as spinal cord injury or post-prostatectomy, offering a painless and effective alternative to oral drugs or invasive treatments.

Specialties

Neurostimulation Erectile Dysfunction Treatment Neuroprosthetics Implantable Medical Devices

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 8400000 MR: - FA: CHF 7.5 Million FAN: 8400000	D: 2025-07-08 FD: 2025-07-08	-

Series A Latest

2025-07-08

$8.4M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Steven Swinson

Chairman of the Board

B

Binzhe Wang

Board Member

N

Nikos Stergiopulos

CSO, Board member and co-founder

LinkedIn (Pro only)

R

Rodrigo Fraga-Silva

CEO, Board member and co-founder

M

Mikael Sturny

CTO and co-founder

F

Fiona Joseph

Head of Clinical Affairs

View 3 more team members with Pro

Unlock Full Team Directory

Recent News

Comphya SA Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised